Search
Search Results
-
Immune Checkpoint Inhibitors in Oncology
In this chapter, we explore the evolution and current state of immune checkpoint inhibitors (ICIs) in cancer treatment, focusing on their mechanism...
-
Endocrine Consequences Following Immune Checkpoint Inhibitors Therapy
Immune checkpoint inhibitors (ICIs) are a novel drug category enhancing the patient’s immune response against tumors. Their approval in cancer...
-
Synthetic viability induces resistance to immune checkpoint inhibitors in cancer cells
BackgroundImmune checkpoint inhibitors (ICI) have revolutionized the treatment for multiple cancers. However, most of patients encounter resistance....
-
Immune checkpoint inhibitors in gastrointestinal malignancies: an Umbrella review
In the Modern era, immune checkpoint inhibitors (ICIs) have been the cornerstone of success in the treatment of several malignancies. Despite...
-
Immune-related serious adverse events with immune checkpoint inhibitors: Systematic review and network meta-analysis
PurposeImmune checkpoint inhibitors (ICIs) have revolutionized cancer treatment, though uncertainty exists regarding their immune-related safety. The...
-
Exosomal miRNA-146a and miRNA-424 as Possible Predictors of Immune Checkpoint Inhibitors Therapy Response in Clear Cell Renal Cell Carcinoma
AbstractClear cell renal cell carcinoma (ccRCC) is a malignant kidney tumour with a poor prognosis and difficult to treat. Despite significant...
-
Defining clinically useful biomarkers of immune checkpoint inhibitors in solid tumours
Although more than a decade has passed since the approval of immune checkpoint inhibitors (ICIs) for the treatment of melanoma and non-small-cell...
-
An Updated Focus on Immune Checkpoint Inhibitors and Tubulointerstitial Nephritis
One of the most relevant achievements in oncological research is represented by the development of a new category of anticancer drugs, the immune...
-
Interventional pharmacoeconomics for immune checkpoint inhibitors through alternative dosing strategies
Immune checkpoint inhibitors (ICIs) are approved for the treatment of a variety of cancer types. The doses of these drugs, though approved by the...
-
Impact of underlying liver disease on unresectable hepatocellular carcinoma treated with immune checkpoint inhibitors
BackgroundImmune checkpoint inhibitors (ICIs) are standard therapy for unresectable HCC, but many patients do not respond. Non-viral HCC,...
-
Why does circadian timing of administration matter for immune checkpoint inhibitors’ efficacy?
BackgroundTolerability and antitumour efficacy of chemotherapy and radiation therapy can vary largely according to their time of administration along...
-
Diagnosis and Management of Immune-Related Adverse Events of Immune Checkpoint Inhibitor Therapy
The landscape of cancer therapy has undergone a profound transformation in the last decade, shifting from traditional cytotoxic chemotherapy to the...
-
Immune checkpoint inhibitors alone vs immune checkpoint inhibitors—combined chemotherapy for NSCLC patients with high PD-L1 expression: a network meta-analysis
BackgroundWe indirectly compared the effects of immune checkpoint inhibitors alone (ICI) and ICI-combined chemotherapy (chemo-ICI) in patients with...
-
Alpha-fetoprotein predicts the treatment efficacy of immune checkpoint inhibitors for gastric cancer patients
BackgroundImmune checkpoint inhibitors (ICIs) are commonly used in conjunction with chemotherapy to improve treatment outcomes for patients with...
-
GRIN2A mutation is a novel indicator of stratifying beneficiaries of immune checkpoint inhibitors in multiple cancers
Glutamate-NMDAR receptors (GRINs) have been reported to influence cancer immunogenicity; however, the relationship between GRIN alterations and the...
-
Dissecting the tumor microenvironment in response to immune checkpoint inhibitors via single-cell and spatial transcriptomics
Cancer is a disease that undergoes selective pressure to evolve during its progression, becoming increasingly heterogeneous. Tumoral heterogeneity...
-
Immune-checkpoint inhibitor-mediated myocarditis: CTLA4, PD1 and LAG3 in the heart
Immune-checkpoint inhibitors (ICIs) have revolutionized oncology, with nearly 50% of all patients with cancer eligible for treatment with ICIs....
-
Exploring the prognostic impact of absolute lymphocyte count in patients treated with immune-checkpoint inhibitors
BackgroundThe role of immune checkpoint inhibitors (ICI) expands but affordable and reproducible prognostic biomarkers are needed. We investigated...
-
Immune checkpoint inhibitor (ICI) genes and aging in malignant melanoma patients: a clinicogenomic TCGA study
BackgroundCancer diagnoses and deaths among the elderly (65 +) are expected to increase significantly over the next decade. Immune checkpoint...
-
Autoimmune PaneLs as PrEdictors of Toxicity in Patients TReated with Immune Checkpoint InhibiTors (ALERT)
BackgroundImmune-checkpoint inhibitors (ICI) can lead to immune-related adverse events (irAEs) in a significant proportion of patients. The...
